Biotangents Secures £2.3m for Dairy Farming Innovation

Deal News | Nov 29, 2024 | Scottish Enterprise

Biotangents Secures £2.3m for Dairy Farming Innovation

Biotangents, a company pioneering innovative solutions in the dairy farming industry, has secured a £2.3 million investment to advance its projects. The funding round was led by Eos Advisory, a firm based in St Andrews, and includes contributions from British Business Investments as part of their Regional Angels Programme, as well as existing investors Kelvin Capital and Scottish Enterprise. The infusion of capital will aid Biotangents in its mission to transform dairy farming practices through technological advancements.

Sectors

  • Agriculture Technology
  • Private Equity and Venture Capital

Geography

  • United Kingdom – The investment involves multiple stakeholders from the UK, including Eos Advisory and Scottish Enterprise.
  • Scotland – Eos Advisory, a key leader in the investment, is based in St Andrews, Scotland, highlighting the regional focus of the transaction.

Industry

  • Agriculture Technology – Biotangents is working on innovative solutions for the dairy farming industry, classifying it within the AgriTech sector.
  • Private Equity and Venture Capital – The article discusses an investment round led by Eos Advisory and supported by private equity entities like Kelvin Capital and public bodies like Scottish Enterprise.

Financials

  • £2.3m – Total investment amount garnered by Biotangents in the funding round.

Participants

NameRoleTypeDescription
BiotangentsTargetCompanyBiotangents is a company focused on advancing technology in the dairy farming industry.
Eos AdvisoryLead InvestorCompanyEos Advisory, based in St Andrews, led the investment round in Biotangents.
British Business InvestmentsInvestorCompanyParticipated in the investment round through their Regional Angels Programme.
Kelvin CapitalInvestorCompanyExisting investor in Biotangents participating in the funding round.
Scottish EnterpriseInvestorCompanyExisting investor in Biotangents and supporter in the recent investment round.